EGFR and colorectal carcinoma: The feedback activation of epidermal growth factor receptor (EGFR)-mediated wild-type RAS signalling contributes to the reduced effectiveness of KRASG12D inhibitor therapy in CRC, unveiling the role of MRTX1133 in KARSG12D mutant CRC[17].